PRAX on Nasdaq

Praxis Precision Medicines, Inc.

American pharmaceutical preparations company, incorporated in Delaware.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with Roivant, BioAge Labs, Inc. or RedHill Biopharma Ltd., or pick any stock.

TickerPRAX on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address99 High Street, 30Th Floor, Boston, Ma 02110²
Filer categoryLarge accelerated filer²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 2025³

-34.5%Return on equity³

-$249.1MFree cash flow³

Financial statements

Revenue⁴³$0 in 2025

Operating income⁵⁶⁷⁴³-$326.2M in 2025+811% since 2019

Net income⁵⁶⁷⁴³-$303.3M in 2025+754% since 2019

Every line of the income statement as filed: the last 3 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31	2023-12-31
Collaboration revenue	$0	$8.6M	$2.4M
Research and development	$267.1M	$152.4M	$86.8M
General and administrative	$59.1M	$56.3M	$42.1M
Total operating expenses	$326.2M	$208.7M	$128.8M
Loss from operations	-$326.2M	-$200.2M	-$126.4M
Other income, net	$22.9M	$17.3M	$3.1M
Total other income	$22.9M	$17.3M	$3.1M
Net loss	-$303.3M	-$182.8M	-$123.3M
Net loss per share attributable to common stockholders, basic (in dollars per share)	-$13.48	-$10.21	-$18.69
Net loss per share attributable to common stockholders, diluted (in dollars per share)	-$13.48	-$10.21	-$18.69
Weighted average common shares outstanding, basic (in shares)	22.5M shares	17.9M shares	6.6M shares
Weighted average common shares outstanding, diluted (in shares)	22.5M shares	17.9M shares	6.6M shares

Total assets⁵⁶⁷⁴¹⁰³$937.9M in 2025+1867% since 2019

Total liabilities⁵⁶⁷⁴¹⁰³$59.8M in 2025+688% since 2019

Shareholders’ equity⁶⁷⁴³$878.1M in 2025

Cash⁵⁶⁷⁴³$357.3M in 2025+697% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.³

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and cash equivalents	$357.3M	$215.4M	$81.3M
Marketable securities	$242.0M	$177.2M
Prepaid expenses and other current assets	$11.6M	$11.8M
Total current assets	$610.9M	$404.4M
Long-term marketable securities	$326.8M	$77.0M
Property and equipment, net	$147.0K	$230.0K
Operating lease right-of-use assets	$92.0K	$1.1M
Other non-current assets	$0	$416.0K
Total assets	$937.9M	$483.1M
Accounts payable	$24.6M	$12.5M
Accrued expenses	$35.0M	$23.8M
Operating lease liabilities	$110.0K	$1.3M
Total current liabilities	$59.8M	$37.5M
Non-current portion of operating lease liabilities	$0	$110.0K
Total liabilities	$59.8M	$37.7M
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and December 31, 2024	$0	$0
Common stock, $0.0001 par value; 150,000,000 shares authorized; 25,195,092 shares issued and outstanding as of December 31, 2025, and 19,422,358 shares issued and outstanding as of December 31, 2024	$15.0K	$14.0K
Additional paid-in capital	$2.0B	$1.3B
Accumulated deficit	-$1.1B	-$836.7M
Accumulated other comprehensive gain	$563.0K	$654.0K
Total stockholders equity	$878.1M	$445.4M	$69.7M	$76.1M
Total liabilities and stockholders equity	$937.9M	$483.1M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized (in shares)	10.0M shares	10.0M shares
Preferred stock, issued (in shares)	0 shares	0 shares
Preferred stock, outstanding (in shares)	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	150.0M shares	150.0M shares
Common stock, outstanding (in shares)	25.2M shares	19.4M shares
Common stock, issued (in shares)	25.2M shares	19.4M shares

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and cash equivalents	$357.3M	$215.4M	$81.3M
Marketable securities	$242.0M	$177.2M
Prepaid expenses and other current assets	$11.6M	$11.8M
Total current assets	$610.9M	$404.4M
Long-term marketable securities	$326.8M	$77.0M
Property and equipment, net	$147.0K	$230.0K
Operating lease right-of-use assets	$92.0K	$1.1M
Other non-current assets	$0	$416.0K
Total assets	$937.9M	$483.1M
Accounts payable	$24.6M	$12.5M
Accrued expenses	$35.0M	$23.8M
Operating lease liabilities	$110.0K	$1.3M
Total current liabilities	$59.8M	$37.5M
Non-current portion of operating lease liabilities	$0	$110.0K
Total liabilities	$59.8M	$37.7M
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and December 31, 2024	$0	$0
Common stock, $0.0001 par value; 150,000,000 shares authorized; 25,195,092 shares issued and outstanding as of December 31, 2025, and 19,422,358 shares issued and outstanding as of December 31, 2024	$15.0K	$14.0K
Additional paid-in capital	$2.0B	$1.3B
Accumulated deficit	-$1.1B	-$836.7M
Accumulated other comprehensive gain	$563.0K	$654.0K
Total stockholders equity	$878.1M	$445.4M	$69.7M	$76.1M
Total liabilities and stockholders equity	$937.9M	$483.1M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, authorized (in shares)	10.0M shares	10.0M shares
Preferred stock, issued (in shares)	0 shares	0 shares
Preferred stock, outstanding (in shares)	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	150.0M shares	150.0M shares
Common stock, outstanding (in shares)	25.2M shares	19.4M shares
Common stock, issued (in shares)	25.2M shares	19.4M shares

Cash from operations⁵⁶⁷⁴³-$249.1M in 2025+645% since 2019

Capital spending⁵⁶⁷⁴³$56.0K in 2025−46% since 2019

Free cash flow⁵⁶⁷⁴³-$249.1M in 2025+643% since 2019

Every line of the cash flow as filed: the last 3 fiscal years, latest first.³

Period ending	2025-12-31	2024-12-31	2023-12-31
Net loss	-$303.3M	-$182.8M	-$123.3M
Depreciation expense	$140.0K	$358.0K	$432.0K
Stock-based compensation expense	$33.9M	$41.4M	$24.9M
Non-cash operating lease expense	$1.0M	$933.0K	$837.0K
Amortization of premiums and discounts on marketable securities, net	-$3.6M	-$5.0M	$47.0K
Non-cash collaboration and license agreement expense	$0	$2.5M	$0
Other non-cash adjustments	-$7.0K	$0	$0
Prepaid expenses and other current assets	$640.0K	-$8.2M	$6.8M
Accounts payable	$12.1M	$6.7M	-$8.9M
Accrued expenses	$11.2M	$16.1M	-$8.5M
Operating lease liabilities	-$1.3M	-$1.1M	-$1.0M
Deferred revenue	$0	-$2.6M	-$2.4M
Other	$0	$2.0K	$0
Net cash used in operating activities	-$249.1M	-$131.8M	-$111.1M
Purchases of property and equipment	-$56.0K	$0	-$50.0K
Purchases of marketable securities	-$623.8M	-$371.5M	$0
Maturities of marketable securities	$312.7M	$123.0M	$39.0M
Net cash (used in) provided by investing activities	-$311.1M	-$248.5M	$39.0M
Payments of tax withholdings related to vesting of restricted stock units	-$2.1M	-$308.0K	-$137.0K
Proceeds from exercise of options and employee stock purchase plan purchases	$13.3M	$2.6M	$416.0K
Net cash provided by financing activities	$702.2M	$514.3M	$91.9M
Increase in cash, cash equivalents and restricted cash	$142.0M	$134.1M	$19.7M

Compare Praxis Precision Medicines, Inc. with another company

Leadership

Who has led Praxis Precision Medicines, Inc., and when. Pick a name to see everywhere that person has worked.

2025

Chief executive officerMarcio Souza Oct 15, 2020 to now¹¹
PresidentMarcio Souza Jan 11, 2022 to Jan 11, 2022¹²
Chief financial officerStuart Chaffee Oct 15, 2020 to Oct 15, 2020¹³
Chief operating officerMegan Sniecinski Jan 9, 2026 to now¹⁴

Board members and other officers (16)

Chief Medical OfficerBernard Ravina Oct 15, 2020 to Jun 24, 2022¹⁵
Principal Accounting OfficerLauren Mastrocola Oct 15, 2020 to now¹⁶
Chief Commercial OfficerNicole Sweeny Oct 15, 2020 to Feb 13, 2023¹⁷
Board memberJeffrey B. Kindler Jan 12, 2026 to now¹⁸
Board memberStuart A. Arbuckle Jan 12, 2026 to now¹⁹
Board memberJill Desimone May 24, 2022 to now²⁰
Board memberJeffrey Chodakewitz Apr 15, 2021 to now²¹
Board memberMerit Ester Cudkowicz Apr 30, 2021 to now²²
Board memberDean J. Mitchell Oct 15, 2020 to now²³
Board memberGregory Norden Oct 15, 2020 to now²⁴
Board memberKiran Reddy Oct 15, 2020 to Oct 15, 2020²⁵
Board memberNicholas Galakatos Oct 15, 2020 to Oct 15, 2020²⁶
Board memberStefan Vitorovic Oct 15, 2020 to May 27, 2022²⁷
Board memberWilliam D. Young Oct 15, 2020 to now²⁸
Board memberMarcio Souza Oct 20, 2020 to now²⁹
General counselAlex Nemiroff Oct 15, 2020 to now³⁰

Timeline

Oct 15, 2020New chief executive Marcio Souza becomes CEO¹¹

Filings

401 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 77 major events, 157 insider forms, 98 large holders, 49 other. The latest 20:

Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 6, 202610-Q EDGAR
Aug 6, 20268-K EDGAR
Jul 8, 20264 EDGAR
Jul 7, 20268-K EDGAR
Jul 2, 20268-K EDGAR
Jun 29, 20268-K EDGAR
Jun 26, 20264 EDGAR
Jun 24, 2026144 EDGAR
Jun 22, 20268-K EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20268-K EDGAR
Jun 1, 20268-K EDGAR

The 401 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 98 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Jupiter Topco LLC	3,421,374	$1.1B	0.5%	New
Fmr LLC	2,316,907	$775.7M	0.0%	+155,964
BlackRock, Inc.	2,292,585	$767.5M	0.0%	−32,344
Perceptive Advisors LLC	2,035,986	$681.6M	10.6%	No change
Baker Bros. Advisors LP	1,753,198	$587.0M	3.0%	No change
Orbis Allan Gray Ltd	1,529,788	$512.2M	1.8%	−942,692
Vanguard Portfolio Management LLC	1,335,185	$447.0M	0.0%	+578,437
Vanguard Capital Management LLC	1,235,299	$413.6M	0.0%	+13,355
State Street Corp	1,026,443	$343.7M	0.0%	+142,205
Adage Capital Partners Gp, L.l.c.	1,015,480	$340.0M	0.5%	+199,741
Deerfield Management Company, L.P.	963,351	$322.5M	4.0%	No change
Driehaus Capital Management LLC	959,048	$321.1M	1.9%	+9,823
Morgan Stanley	854,112	$285.9M	0.0%	+20,621
Geode Capital Management, LLC	748,039	$250.5M	0.0%	+97,135
Cormorant Asset Management, LP	640,000	$214.3M	11.0%	−245,500
Goldman Sachs Group Inc	548,830	$183.7M	0.0%	−161,904
Bank Of America Corp /de/	546,930	$183.1M	0.0%	+12,326
Invesco Ltd.	537,548	$180.0M	0.0%	+476,151
Hood River Capital Management LLC	425,167	$142.3M	1.0%	+66,549
Norges Bank	346,969	$116.2M	0.0%	New
Franklin Resources Inc	327,124	$109.5M	0.0%	+51,001
Pictet Asset Management Holding SA	291,689	$98.0M	0.1%	+5,045
Polar Capital Holdings Plc	279,131	$93.5M	0.3%	New
Vivo Capital, LLC	271,116	$90.8M	8.3%	−67,779
Logos Global Management LP	260,000	$87.0M	3.7%	−25,000

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

Date	Member	Trade	Amount	Vs S&P since	Filing
Sep 29, 2026	Gilbert Ray Cisneros, Jr.Democratic, House	Buy	$1,001 - $15,000	−12.7%	Report
Jul 30, 2026	Gilbert Ray Cisneros, Jr.Democratic, House	Buy	$1,001 - $15,000	−23.4%	Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARPraxis Precision Medicines, Inc. filings on SEC EDGAR
2
SEC EDGARPraxis Precision Medicines, Inc. filings on SEC EDGAR
3
SEC EDGARPraxis Precision Medicines, Inc. 10-K for fiscal 2025
4
SEC EDGARPraxis Precision Medicines, Inc. 10-K for fiscal 2022
5
SEC EDGARPraxis Precision Medicines, Inc. 10-K for fiscal 2019
6
SEC EDGARPraxis Precision Medicines, Inc. 10-K for fiscal 2020
7
SEC EDGARPraxis Precision Medicines, Inc. 10-K for fiscal 2021
8
SEC EDGARPraxis Precision Medicines, Inc. 10-Q for fiscal 2026
9
SEC EDGARPraxis Precision Medicines, Inc. 10-Q for fiscal 2026
10
SEC EDGARPraxis Precision Medicines, Inc. 10-K for fiscal 2023
11
SEC EDGARMarcio Souza, Chief executive officer
12
SEC EDGARMarcio Souza, President
13
SEC EDGARStuart Chaffee, Chief financial officer
14
SEC EDGARMegan Sniecinski, Chief operating officer
15
SEC EDGARBernard Ravina, Chief Medical Officer
16
SEC EDGARLauren Mastrocola, Principal Accounting Officer
17
SEC EDGARNicole Sweeny, Chief Commercial Officer
18
SEC EDGARJeffrey B. Kindler, Board member
19
SEC EDGARStuart A. Arbuckle, Board member
20
SEC EDGARJill Desimone, Board member
21
SEC EDGARJeffrey Chodakewitz, Board member
22
SEC EDGARMerit Ester Cudkowicz, Board member
23
SEC EDGARDean J. Mitchell, Board member
24
SEC EDGARGregory Norden, Board member
25
SEC EDGARKiran Reddy, Board member
26
SEC EDGARNicholas Galakatos, Board member
27
SEC EDGARStefan Vitorovic, Board member
28
SEC EDGARWilliam D. Young, Board member
29
SEC EDGARMarcio Souza, Board member
30
SEC EDGARAlex Nemiroff, General counsel